Brian Hahn
Equibles does not estimate personal net worth.
About Brian Hahn
Earlier roles on record: CFO at Crescent Biopharma, Inc. (CBIO) until February 21, 2025. Crescent Biopharma, Inc. reported in an 8-K filed June 18, 2025 that Brian Hahn resigned as Principal Executive Officer and Principal Financial Officer, effective June 13, 2025. Crescent Biopharma, Inc. reported in an 8-K filed February 25, 2025 that Brian Hahn resigned as Chief Financial Officer, effective February 21, 2025.
“In addition, on June 13, 2025, Brian Hahn, GlycoMimetics' Principal Executive Officer and Principal Financial Officer, resigned as an executive officer at the Closing.”
“each of Mr. Harout Semerjian, the Chief Executive Officer of the Company and Mr. Brian Hahn, the Company's Chief Financial Officer, ceased his respective employment with the Company as of February 21, 2025 (the "Separation Date").”
Affiliation history
-
Start not stated–2025-02-21